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Open access under CC BY license.Although a live vaccine against Theileria parva has been
available for over 30 years, concerns that vaccine strains
can become established in resident tick populations
have impeded its uptake in endemic areas. Recently,
Oura et al. have examined the persistence of vaccine
strains in immunised cattle using polymorphic genomic
markers. They confirm that elements of the vaccine
establish a carrier state in vaccinated animals and pre-
sent evidence that alleles associated with vaccine strains
emerge in co-grazing non-vaccinated cattle. However,
the epidemiological impact of these observations might
be tempered by extensive recombination of co-ingested
strains in the tick vector.Vaccine-based control strategies for vector-borne
diseases
Vector-borne diseases present several challenges for
vaccine-based control strategies. These include variationsin challenge intensity associated with vector dynamics,
emergence of novel pathogen variants in the vector popu-
lation and the opportunities for immune evasion by the
pathogen through its recombination in the vector. Such
complexities often complicate the prediction of vaccine
performance under field conditions, particularly when
the vaccine itself gives rise to transient patent infection.
Two recent papers by Oura and colleagues [1,2] provide a
powerful insight into these issues with respect to Theileria
parva, an apicomplexan parasite of cattle transmitted by
Rhipicephalus appendiculatus ticks. This parasite invades
and transforms lymphocytes, causing a severe lymphopro-
liferative disease known as East Coast fever (ECF) in
eastern, central and southern Africa.
Theileria parva and ECF
The life cycle of T. parva is similar to that of malaria, with
asexual expansion in the mammalian host and a brief
sexual phase in the arthropod vector. The major replicat-
ing stage is the schizont, which transforms infected
lymphocytes and divides in synchrony with them, ensuring
Box 1. Genotyping with micro- and mini-satellites
Micro- and mini-satellites are stretches of tandemly repeated
nucleotide sequences that are dispersed throughout eukaryotic
genomes, both within genes and in non-coding regions. Micro-
satellites generally comprise short tandem repeats (2–6 bp),
whereas mini-satellites are made up of longer repeating units
(8–100 bp). Satellite loci evolve rapidly through a combination of
replication slippage and meiotic recombination and are often
selectively neutral. As a result, the number of repeated units
occurring at individual satellite loci varies greatly within populations
and constitutes a powerful means of genetic fingerprinting. This is
achieved by PCR amplification of the repeated region using primers
based on flanking sequences. The precision of the fingerprint
obtained is a function of the number of satellite loci examined
across the genome in question.
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pathology associated with ECF is due almost entirely
to dissemination of infected lymphoblasts through lym-
phoid and non-lymphoid tissues. Merozoites released
from a proportion of infected cells after further differen-
tiation of the schizont give rise to transmissible intraer-
ythrocytic piroplasms. Ingestion of piroplasms by a
subsequently feeding tick results in the formation of
gametes and sexual recombination, which give rise ulti-
mately to cattle-infective sporozoite forms in the tick
salivary gland.
Cattle can be immunised against T. parva by simul-
taneous inoculation of live sporozoites and long-acting
formulations of oxytetracycline – widely known as ‘infec-
tion and treatment’ [3,4]. There is strong evidence that
protection is mediated by parasite-specific major histocom-
patibility complex (MHC) class I-restricted cytotoxic T
lymphocytes (CTLs), which target the schizont-infected
lymphoblast [5,6]. Because it does not take effect until
the schizont parasitosis is established, the CTL response
does not prevent infection [6]. In addition, recovered cattle
– and those immunised by infection and treatment – are
almost invariably long-term carriers of piroplasm
forms [7,8]. Because piroplasms of T. parva undergo only
limited replication [9] the carrier state probably arises
from persistence of small numbers of schizont-infected
lymphoblasts.
Parasite diversity and existing vaccines
A key feature of the epidemiology of T. parva and ECF is
the diversity of parasite populations in the field. This is
evident at both antigenic [10,11] and molecular [12–14]
levels and results commonly in a lack of cross-protection
between distinct isolates of the parasite [10,15]. Nonethe-
less, broad protection can be obtained with immunisation
by infection and treatment using relatively few parasite
stocks, suggesting that antigenic variation might be lim-
ited [4]. Although several T. parva isolates have been
evaluated for infection and treatment immunisation, the
formulation used most widely is the original trivalent
vaccine that was developed by Radley et al. in 1975 [4].
Known as theMuguga Cocktail, the formulation comprises
three stocks of the parasite – Muguga, Kiambu 5 and
Serengeti-transformed – and protects against a range of
geographically disparate isolates. The vaccine has been
deployed extensively in Tanzania [16] and Uganda [17]
and, to a lesser extent, in Malawi and southern Zambia.
Diversity of T. parva parasites in the field is also
reflected in the virulence phenotype: some isolates are
highly pathogenic, whereas others give rise to only mild
infections [18]. In addition, the duration of the carrier
state varies following infection with different isolates
[19]. This phenotypic variation and associated concerns
over the consequences of the large-scale introduction of
parasite strains into areas free of them previously
have been significant obstacles to widespread uptake of
immunisation by infection and treatment in some ECF-
endemic countries. Fundamental to these concerns is the
question of whether vaccine strains become established in
the resident tick populations and transmit to unvaccinated
animals.www.sciencedirect.comMolecular tracking of parasite populations following
vaccination
Oura et al. have now provided a powerful insight into this
question by tracking individual components of theMuguga
Cocktail in cattle immunised by infection and treatment
under field conditions in Uganda [1,2]. This was achieved
by PCR amplification of genomic DNA from blood using a
panel of parasitemicro- andmini-satellitemarkers (Box 1).
Based on the numbers of alleles observed with two of the
markers in the composite stabilate, at least six genotypes
are present in the Muguga Cocktail [2]. Moreover, analysis
of samples taken from 14 calves 2 years previously, on day
17 after immunisation, revealed patent infections in all but
two of the animals using both markers, with each calf
harbouring one to three distinct genotypes [2]. All six
alleles of each marker were represented among the calves,
along with an additional product observed in one animal
that was not present in the stabilate. This analysis
confirms that the Muguga Cocktail is complex genotypi-
cally and capable of establishing multiple acute infections
in individual animals.
The group went on to evaluate the persistence of
parasites derived from each component of the cocktail in
immunised animals. Alleles of the two discriminatory
microsatellite markers were allocated to each component
by comparing marker profiles of the stabilate with those of
single cell lines derived from each of the constituent stocks
[1]. However, because each line contained only one geno-
type, it was possible to account for only three out of the six
alleles at either locus. Hence, only one allele at each locus
could be assigned conclusively to individual component
stocks, each of which could theoretically account for up
to four out of the six genotypes. Nonetheless, it was
possible to track the persistence of three of the cocktail
genotypes in immunised cattle, with one representing each
of the component stocks. No evidence was found for the
persistence of the genotypes representing the Muguga or
Serengeti-transformed components in animals vaccinated
previously and, in 13 calves undergoing immunisation,
these were undetectable in all but one animal after
48 days [1]. By contrast, the Kiambu 5-derived genotype
persisted in 70% of cattle, often along with other presum-
ably local genotypes, in some cases 4 years after vaccina-
tion [2]. The transient persistence of the Muguga-derived
element is in line with previous observations of this stock
[19,20]. Given that the genotype associated with the Ser-
Update TRENDS in Parasitology Vol.23 No.12 567engeti-transformed component shares 27 out of 31 marker
alleles with Muguga [1], its predominantly brief carrier
state is perhaps also unsurprising. The close relatedness of
these two genotypes has been reported previously [21] but
is inconsistent with the initial cross-protection studies [3,4]
that led Radley et al. to include it in the cocktail [4]. As
suggested by Oura et al. [1], it is possible that the original
Serengeti-transformed stock (or elements of it) has been
lost in the course of passage. Alternatively, the stock
might contain additional genotypes (perhaps represented
in the unassigned alleles present in the cocktail), which
contribute to the breadth of protection engendered by the
composite vaccine.
Transmission of vaccine components to unvaccinated
animals
The formal demonstration by Oura et al. in these studies
that at least some of the genotypes present in the Muguga
Cocktail establish a persistent carrier state in immunised
cattle confirms that vaccine strains become accessible to
the local tick population and might therefore transmit to
co-grazing animals. This possibility was examined by ana-
lysing blood taken from unvaccinated cattle on the same
farm with several markers that distinguish the Kiambu
5-derived genotype detected in carrier vaccinates [2]. For
each marker, the associated allele was detected in four out
of 13 animals sampled, along with additional alleles,
derived presumably from local stocks. This was interpreted
as strong evidence that the genotype had been transmitted
to these animals from carrier-vaccinated cattle. Although
transmission almost certainly occurred, the notion that
Theileria strains are maintained intact in cattle popu-
lations has been challenged recently [22]. Using a panel
of 64 markers, including some of those described by Oura
et al. [1,2], a stabilate of the Marikebuni isolate of T. parva
was genotyped before and after calf and tick passage. By
genotyping clones derived from parent and daughter popu-
lations, evidence was found for substantial recombination
during the sexual stages of the life cycle. The parent
stabilate was complex genotypically, with 48 genotypes
observed among 231 clones analysed and one accounting
for 75% of the population. Recombination was evident from
the apparent reassortment of alleles in blocks and sub-
stantial inbreeding in relation to the dominant clone [22].
Furthermore, several new variants of each parasite
chromosome were observed in the daughter stabilate
and, although the dominant genotype still accounted for
a high proportion of the clones, none of the other com-
ponents of the parent population were present. Inbreeding
with respect to the dominant genotype was considerably
greater [22]. These observations suggest that T. parva
strains within complex populations are ephemeral, with
alleles reassorting in different combinations during each
tick passage. Given the multiple carrier states observed by
Oura et al. [1,2], it seems unlikely that strains present in
the Muguga Cocktail would escape into the resident tick
population as intact genotypes and persist in the area.
Nonetheless, the results of Oura et al. [1,2] do confirm
that alleles derived from the Muguga Cocktail can trans-
mit to unvaccinated cattle and become incorporated
into the resident parasite gene pool. The epidemiologicalwww.sciencedirect.comsignificance of this remains unclear. Based on a distinct
molecular analysis, Geysen et al. [23] suggested that the
Muguga and Serengeti-transformed components of the
vaccine were prevalent widely among field cases of ECF
in the Southern Province of Zambia, following deployment
of the Muguga Cocktail over a 7 year period. This now
seems unlikely, given the observed absence of these com-
ponents from the carrier animals studied by Oura et al.
[1,2]. In any event, establishment of Kiambu 5 alleles in the
resident parasite population of the farm studied appears to
have been uneventful in terms of disease [2]. The animals
remained under persistent challenge, despite regular acar-
icide treatment, as evidenced by the presence of multiple
parasite genotypes in unvaccinated animals and a history
of severe ECF before implementation of vaccination [1,2].
Concluding remarks and future directions
Perhaps a more important question relates to the genoty-
pic composition of the stocks that make up the Muguga
Cocktail and the possibility that elements could be lost
over time. The former is fundamental to the efficacy of the
vaccine and is likely to change with recombination during
passage of each stock. Consequently, a rigorous definition
of the genotypes present in the Muguga, Kiambu 5 and
Serengeti-transformed stocks that comprise the current
Muguga Cocktail vaccine stabilate appears timely. This
would enable the precise identification of those com-
ponents responsible for the breadth of coverage conferred
by the vaccine and, through the establishment of cloned
stocks, ensure their continued presence in future batches.
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3Vector Control Division, Ministry of Health, 15 Bombo Road, P.O. Box 1661, Kampala, UgandaIn a recent update in this journal [1], Stothard and
Gabrielli highlighted the importance of schistosomiasis in
African infants and preschool children. However, the
authors concluded that, although theevidence is substantial
regarding the importance of the disease in young children,
the under 5-year olds who are also usually less than 94 cm
high should be excluded from large-scale preventive che-
motherapy interventions targeting schistosomiasis control.
The authors argue that it becomes impractical to include
these children because: (i) information documenting the
safety of praziquantel (PZQ) in this age group is lacking;
(ii) PZQ tablets are rejected by children and syrup formu-
lations are not readily available; and (iii) the dose-pole only
works from 94 cm. The authors suggest that primary
healthcare clinics should be the place where infected chil-
dren could get PZQ treatment, although they also refer to
studies showing that the areas with the highest prevalence
of infection in young children are often the areas with the
poorest healthcare facilities. Furthermore, the authors
point to the problem that routine parasitological screening
misses light infections, which is often the case in these
children [2]. Hence, in an attempt to make public health
interventions as simple as possible, the authors have made
it too simple and the consequence of such a recommendation
will be that young children will continue to be denied
treatment. The authors’ argument that it is impractical to
include children in large-scale preventive chemotherapyinterventions is not justifiable ethically. As pointed out by
Olds [3], PZQ is the safest anthelminthic on themarket and
is listed in Pregnancy Category B (i.e. it is a drug presumed
safe based on animal studies) by the US FDA. Second, if
children>1-year-old can takealbendazole andmebendazole
tablets, why can they not takePZQ tablets? Finally, the lack
of a dose-pole to estimate accurately the dose required for
children under 94 cmhigh is not a convincing reason to deny
the age group of their right to treatment; after all, the same
pole could be redesigned to cater for the infants too.
From the early days (1980s) up to today, the control of
schistosomiasis has suffered a great ethical dilemma
because pregnant and lactating women, as well as children
under 5 years old, have been denied PZQ treatment.
However, the denial to mothers has finally been regarded
as unethical because two decades of experience could not
provide any data to support the occurrence of adverse
effects in mothers and their fetuses treated inadvertently
[3–6]. Research within this area is now being considered
a priority and studies are being implemented to assess
the impact of treatment on both mothers and their babies
[6].
The key ethical problem for research relates to the point
of excluding groups or communities whomight benefit from
participation [7]. Equity requires that no group of persons
should be deprived of a fair share of the benefit (e.g.
exclusion from treatment of the under 5-year-olds) because
this results in serious class injustice. This age group has
been denied treatment unjustifiably for too long, whereas,
as pointed out by Stothard and Gabrielli, many studies
